Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.

Kitamoto T, Yoshino M, Shingaki T, Oura T, Gomez Valderas E, Dunn JP

Current medical research and opinion1 Jun 2026

PMID42434924DOI10.1080/03007995.2026.2695047PepBankPUB-42434924

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults who met Japanese obesity disease criteria, tirzepatide reduced body weight more than semaglutide at Week 72 (-20.1% versus -12.9%).
In plain wordsIn adults with obesity disease, tirzepatide lowered body weight more than semaglutide over 72 weeks.
Peptide
Tirzepatide
Outcome
DecreasePercent change in body weight at Week 72
Study
n = 383
Comparator
Semaglutide 2.4 mg or MTD
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg or maximum tolerated dose · 72 weeksAs given in this study (human).
Measurements
LSM percent change in body weight
−20.1%
tirzepatide
LSM difference versus semaglutide
−7.2%
tirzepatide minus semaglutide
Source sentences
Summary
At Week 72, the least-squares mean (LSM) percent change in body weight was significantly greater for tirzepatide (-20.1% [SE 0.76%]) versus semaglutide (-12.9% [0.74%]), with an LSM difference of -7.2 (95% CI = -9.3 to -5.1; p <.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m² and ≥2 obesity-related health disorders (ORHDs), or BMI ≥35 kg/m² with ≥1 ORHD.
Summary · context
Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], n = 190; semaglutide 2.4 mg or MTD, n = 193).
Report a problemFND-4243492401
02HumanRandomized controlled trialEfficacy outcome
In adults who met Japanese obesity disease criteria, more participants receiving tirzepatide than semaglutide reached each weight-loss target from 10% to 30%.
In plain wordsIn adults with obesity disease, more people on tirzepatide than on semaglutide reached each weight-loss target.
Peptide
Tirzepatide
Outcome
IncreaseProportion reaching weight-loss targets of 10%, 15%, 20%, 25% and 30% or more
Study
n = 383
Comparator
Semaglutide 2.4 mg or MTD
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg or maximum tolerated dose · 72 weeksAs given in this study (human).
Source sentences
Summary
More participants receiving tirzepatide achieved ≥10%, ≥15%, ≥20%, ≥25%, and ≥30% weight-loss targets.
2 context sentences(design, population, supporting numbers)
Summary · context
This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m² and ≥2 obesity-related health disorders (ORHDs), or BMI ≥35 kg/m² with ≥1 ORHD.
Summary · context
Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], n = 190; semaglutide 2.4 mg or MTD, n = 193).
Report a problemFND-4243492402
03HumanRandomized controlled trialEfficacy outcome
In adults who met Japanese obesity disease criteria, tirzepatide reduced waist circumference significantly more than semaglutide, from Week 4 through Week 72.
In plain wordsIn adults with obesity disease, tirzepatide cut waist size more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n = 383
Comparator
Semaglutide 2.4 mg or MTD
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg or maximum tolerated dose · 72 weeksAs given in this study (human).
Source sentences
Summary
Reductions in waist circumference and BMI were significantly greater with tirzepatide, evident from Weeks 4 and 12, respectively, and maintained through Week 72.
2 context sentences(design, population, supporting numbers)
Summary · context
This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m² and ≥2 obesity-related health disorders (ORHDs), or BMI ≥35 kg/m² with ≥1 ORHD.
Summary · context
Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], n = 190; semaglutide 2.4 mg or MTD, n = 193).
Report a problemFND-4243492403
04HumanRandomized controlled trialEfficacy outcome
In adults who met Japanese obesity disease criteria, tirzepatide reduced BMI significantly more than semaglutide, from Week 12 through Week 72.
In plain wordsIn adults with obesity disease, tirzepatide lowered body mass index more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseBody mass index
Study
n = 383
Comparator
Semaglutide 2.4 mg or MTD
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg or maximum tolerated dose · 72 weeksAs given in this study (human).
Source sentences
Summary
Reductions in waist circumference and BMI were significantly greater with tirzepatide, evident from Weeks 4 and 12, respectively, and maintained through Week 72.
2 context sentences(design, population, supporting numbers)
Summary · context
This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m² and ≥2 obesity-related health disorders (ORHDs), or BMI ≥35 kg/m² with ≥1 ORHD.
Summary · context
Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], n = 190; semaglutide 2.4 mg or MTD, n = 193).
Report a problemFND-4243492404
05HumanRandomized controlled trialEfficacy outcome
In adults who met Japanese obesity disease criteria, semaglutide reduced body weight by 12.9% (least-squares mean) at Week 72, less than tirzepatide.
In plain wordsIn adults with obesity disease, semaglutide lowered body weight over 72 weeks, but less than tirzepatide.
Peptide
Semaglutide
Outcome
DecreasePercent change in body weight at Week 72
Study
n = 193
Comparator
Tirzepatide 15 mg or MTD
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg or maximum tolerated dose · 72 weeksAs given in this study (human).
Measurements
LSM percent change in body weight
−12.9%
semaglutide
Source sentences
Summary
At Week 72, the least-squares mean (LSM) percent change in body weight was significantly greater for tirzepatide (-20.1% [SE 0.76%]) versus semaglutide (-12.9% [0.74%]), with an LSM difference of -7.2 (95% CI = -9.3 to -5.1; p <.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m² and ≥2 obesity-related health disorders (ORHDs), or BMI ≥35 kg/m² with ≥1 ORHD.
Summary · context
Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], n = 190; semaglutide 2.4 mg or MTD, n = 193).
Report a problemFND-4243492406
06HumanRandomized controlled trialSafety outcome
In adults who met Japanese obesity disease criteria, the safety profile of semaglutide was generally consistent with the overall SURMOUNT-5 population, with gastrointestinal events most common.
In plain wordsIn adults with obesity disease, semaglutide had safety similar to the full trial, and stomach and gut problems were the most common.
Peptide
Semaglutide
Outcome
Direction not reportedSafety profile and gastrointestinal events
Study
n = 193
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2.4 mg or maximum tolerated dose · 72 weeksAs given in this study (human).
Source sentences
Summary
The safety profile was generally consistent with the overall SURMOUNT‑5 population, with gastrointestinal events most common.
2 context sentences(design, population, supporting numbers)
Summary · context
This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m² and ≥2 obesity-related health disorders (ORHDs), or BMI ≥35 kg/m² with ≥1 ORHD.
Summary · context
Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], n = 190; semaglutide 2.4 mg or MTD, n = 193).
Report a problemFND-4243492407
07HumanRandomized controlled trialSafety outcome
In adults who met Japanese obesity disease criteria, the safety profile of tirzepatide was generally consistent with the overall SURMOUNT-5 population, with gastrointestinal events most common.
In plain wordsIn adults with obesity disease, tirzepatide had safety similar to the full trial, and stomach and gut problems were the most common.
Peptide
Tirzepatide
Outcome
Direction not reportedSafety profile and gastrointestinal events
Study
n = 190
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mg or maximum tolerated dose · 72 weeksAs given in this study (human).
Source sentences
Summary
The safety profile was generally consistent with the overall SURMOUNT‑5 population, with gastrointestinal events most common.
2 context sentences(design, population, supporting numbers)
Summary · context
This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m² and ≥2 obesity-related health disorders (ORHDs), or BMI ≥35 kg/m² with ≥1 ORHD.
Summary · context
Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], n = 190; semaglutide 2.4 mg or MTD, n = 193).
Report a problemFND-4243492405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT05822830

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Eli Lilly and Companyn = 75121 Apr 2023 to 13 Nov 2024

Obesity · Overweight

Trial page ClinicalTrials.govUpdated 26 Nov 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.